RxDoctor Payments DataLook up a doctor →

Jun Sun, MD

Hematology & Oncology · Clinton, MDNPI 1306097209

Payments from drug & device makers

$216,193in general payments, 2019–2025

Across 866 payments — averaging $249.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AVEO Pharmaceuticals, Inc.$57K
  • Gilead$38K
  • Amgen$36K
  • Novartis$18K
  • Incyte Corporation$17K
  • Regeneron$7K
  • plus $41K from 54 others

What the payments were for

  • Consulting fees$24,94852%
  • Speaking & faculty fees$3,9308%
  • Travel & lodging$6611%
  • Food & beverage$17,58837%
  • Education$4101%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AVEO Pharmaceuticals, Inc.21$57,138
Gilead(2 entities)37$38,175
Amgen35$36,495
Novartis45$18,322
Incyte Corporation32$17,347
Regeneron9$6,880
AstraZeneca(2 entities)46$6,297
Karyopharm Therapeutics Inc.12$5,515
Global Blood Therapeutics, Inc.5$5,135
Exelixis Inc.17$3,898
Bristol Myers Squibb15$2,805
Immunomedics, Inc.2$2,732
Johnson & Johnson(2 entities)52$2,291
Pfizer65$1,247
Merck50$1,042
E.r. Squibb & Sons, L.L.C.30$713
Daiichi Sankyo Inc.26$692
AbbVie11$634
Puma Biotechnology, Inc.7$622
Genentech USA, Inc.27$604
Astellas Pharma US Inc28$571
Sanofi16$512
Seagen Inc.16$436
Lilly USA, LLC21$396
Eisai Inc.17$351
Takeda Pharmaceuticals U.S.A., Inc.16$350
Bayer13$280
Beigene USA, Inc.10$276
Pharmaessentia USA Corporation8$229
GSK8$203
Stemline Therapeutics Inc.7$190
Ipsen Biopharmaceuticals, Inc7$183
EMD Serono, Inc.7$178
Secura Bio, Inc.2$173
Pharmacyclics LLC, An Abbvie Company7$170
Regeneron Healthcare Solutions, Inc.7$168
Boehringer Ingelheim7$168
Array Biopharma Inc8$163
Tersera Therapeutics LLC5$140
Mirati Therapeutics, Inc.4$133
Rigel Pharmaceuticals, Inc.5$129
Taiho Oncology, Inc.6$124
Genmab U.S., Inc.4$121
ADC Therapeutics America, Inc.4$104
Sumitomo Pharma America, Inc.5$101
Spectrum Pharmaceuticals Inc.4$94
Adaptive Biotechnologies Corporation5$85
Blueprint Medicines Corporation4$81
Kyowa Kirin, Inc.4$80
Coherus Oncology, Inc.4$74
Myovant Sciences Inc.3$67
G1 Therapeutics, Inc.3$66
Novocure Inc.2$59
Covidien LP1$57
Sobi, Inc3$56
Beone Medicines USA, Inc.2$54
Servier Pharmaceuticals LLC3$51
Sirtex Medical Inc2$49
Morphosys, US Inc.2$48
CTI Biopharma Corp.3$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,193 in reported general payments places this provider in the 75th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$4,396,613
Medicare patients
954
Services billed
233,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide39$894,478
Lenalidomide46$536,683
TagrissoOsimertinib Mesylate14$236,777
JakafiRuxolitinib Phosphate12$210,680
EliquisApixaban224$187,459
GilotrifAfatinib Dimaleate11$127,995
Fondaparinux Sodium36$64,148
XareltoRivaroxaban38$46,764
Enoxaparin Sodium19$4,345
Exemestane30$4,331
Oxycodone Hcl47$1,235
Acyclovir31$932
Letrozole25$898
Allopurinol23$539
Hydroxyurea18$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$713$894,47839 claims
AstraZenecaTagrisso$6,297$236,77714 claims
Incyte CorporationJakafi$17,347$210,68012 claims
PfizerEliquis$1,247$187,459224 claims
Boehringer IngelheimGilotrif$168$127,99511 claims
Johnson & JohnsonXarelto$2,291$46,76438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 242 hematology & oncology providers in Maryland.

Other hematology & oncology in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →